Paclitaxel activity in anthracycline refractory breast cancer patients

Tumori

Volumn 83, Issue 3, 1997, Pages 661-664

  Vici, Patrizia ^a   Di Lauro, Luigi ^a   Conti, Francesca ^a   Capomolla, Elisabetta ^a   Gionfra, Tommaso ^a   Amodio, Antonella ^a   Lopez, Massimo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

anthracycline resistance; paclitaxel; pretreated breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; ORPHENADRINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CASE REPORT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 0030847116     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169708300307     Document Type: Article

References (26)

1. Abrams J.S., Vena D.A., Baltz J., Adams J., Montello M., Christian M., Onetto N., Desmond-Hellmann S., Canetta R.F., Friedman M.A., Arbuck S.G.: Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J. Clin. Oncol., 13: 2056-2060, 1995.
2. Cabral F.R., Barlow S.B.: Mechanisms by which mammalian cells aquire resistance to drugs that affect micrutubule assembly. FASEB J., 3: 1593-1599, 1989.
3. Cabral F., Wible L., Brenner S., Brinkley B.R.: Taxol-requiring mutants of Chinese hamster ovary cells with impaired mitotic spindle activity. J. Cell. Biol., 97: 30-39, 1983.
4. Chervinsky D.S., Brecher M.L., Hoelcle M.J.: Cremophor-EL enanches taxol activity in a multi-drug resistant c1300 neuroblastoma cell line. Anticancer Res., 13: 93-96, 1993.
5. Clark G.M., Sledge G.W., Osborne C.K., McGuire W.L.: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J. Clin. Oncol., 5: 55-61, 1987.
6. Currow D., D'Souza D., Clarke S.J., Gurney H.P., Harnett P.R., Kefford R.F.: Paclitaxel in heavily pretreated breast cancer (Abst.). Proc. Am. Soc. Clin. Oncol., 14: 134, 1995.
7. Deuchars K.L., Ling V.: P-glycoprotein: multidrug resistance in cancer chemotherapy. Semin. Oncol., 16: 156-165, 1989.
8. De Vita V.T.: Principles of chemotherapy. In: Cancer. Principles & practice of oncology, De Vita V.T., Hellman S., Rosenberg S.A. (Eds.), pp. 276-292, Lippincott, Philadelphia, 1993.
9. Flamm Honig S.: Treatment of metastatic disease: hormonal therapy and chemotherapy. In: Diseases of the breast, Harris J.R., Lippman M.E., Morrow M., Hellman S. (Eds.), pp. 669-734, Lippincott-Raven, Philadelphia, 1996.
10. Fountzilas G., Athanassiades A., Giannakakis T., Bafaloukos D, Karakousis K., Dombros N., Kosmidis P., Skarlos D.: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur. J. Cancer, 32: 47-51, 1996.
11. Gianni L., Capri G., Munzone E., Straneo M.: Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin. Oncol., 21: 29-33, 1994.
12. Gupta R.S.: Cross-resistance of vinblastine and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat. Rep., 69: 515-521, 1985.
13. Holmes F.A., Valero V., Theriault R.L., Walters R.S., Booser D.B., Frye D., Hortobagyi G.N.: Phase II trial of taxol in metastatic breast cancer refractory to multiple prior treatments (Abst.). Proc. Am. Soc. Clin. Oncol., 12: 94, 1993.
14. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., Buzdar A.D., Frye D.K., Hortobagyi G.N.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805, 1991.
15. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
16. Manfredi J.J., Horwitz S.B.: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther., 25: 83-125, 1984.
17. Mick R., Begg C.B., Antman K.H., Korzun A.H., Frei E.: Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res. Treat., 13: 33-38, 1989.
18. Miller A.B., Hoogstraten B., Staquet M., Winkler A.: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
19. Nabholtz J.M., Gelmon K., Bontebal M., Spielmann M., Catimel G., Conte P., Klassen U., Namer M., Bonneterre J., Fumoleau P., Winograd B.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol., 14: 1858-1867, 1996.
20. Reichman B.S., Seidman A.D., Crown J.P.S.A., Heelan R., Hakes T.B., Lebwohl D.E., Gilewski T.A., Surbone A., Currie V., Hudis C.A., Yao T.J., Klecker R., Jamis-Dow C., Collins J., Quinlivan S., Berkery R., Toomasi F., Canetta R., Fisherman J., Arbuck S., Norton L.: Taxol and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol., 11: 1943-1951, 1993.
21. Salmon S.E., Grogan T.M., Miller T., Scheper R., Dalton W.S.: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J. Natl. Cancer Inst., 81: 696-701, 1989.
22. Sanfilippo O., Ronchi E., De Marco C., Di Fronzo G., Silvestrini R.: Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer, 27: 155-158, 1991.
23. Seidman A.D.: The emerging role of paclitaxel in breast cancer therapy. Clin. Cancer, Res., 1: 247-256, 1995.
24. Seidman A.D., Reichman B.S., Crown J.P.A., Yao T.J., Currie V., Hakes T.B., Hudis C.A., Gilewski T.A., Baselga J., Forsythe P., Lepore J., Marks L., Fain K., Souhrada M., Onetto N., Arbuck S., Norton L.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol., 13: 1152-1159, 1995.
25. Seidman A.D., Tiersten A., Hudis C., Gollub M., Barret S., Yao T.J., Lepore J., Gilewski T., Currie V., Crown J., Hakes T., Baselga J., Sklarin N., Moynihan M.E., Tong W., Kearns C., Spriggs C., Norton L.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol., 13: 2575-2581, 1995.
26. Webster L., Linenmyer M., Millward M., Morton C., Bishop J., Woodcock D.: Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst., 85: 1685-1690, 1993.